JPMorgan Chase & Co. Buys 211,654 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS)

JPMorgan Chase & Co. increased its stake in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 141.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 361,296 shares of the company’s stock after acquiring an additional 211,654 shares during the period. JPMorgan Chase & Co. owned 0.29% of Atossa Therapeutics worth $341,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the stock. Gallagher Capital Advisors LLC bought a new position in shares of Atossa Therapeutics in the fourth quarter worth about $25,000. Intech Investment Management LLC increased its position in Atossa Therapeutics by 224.0% in the 4th quarter. Intech Investment Management LLC now owns 62,844 shares of the company’s stock worth $59,000 after buying an additional 43,449 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Atossa Therapeutics by 1.6% during the third quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company’s stock worth $4,278,000 after buying an additional 44,762 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of Atossa Therapeutics by 148.2% during the fourth quarter. SG Americas Securities LLC now owns 103,865 shares of the company’s stock worth $98,000 after buying an additional 62,016 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Atossa Therapeutics by 280.9% in the third quarter. Barclays PLC now owns 167,718 shares of the company’s stock valued at $255,000 after acquiring an additional 123,683 shares during the period. 12.74% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ATOS has been the topic of a number of research reports. Ascendiant Capital Markets boosted their target price on shares of Atossa Therapeutics from $7.00 to $7.25 and gave the stock a “buy” rating in a research report on Monday, April 21st. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Atossa Therapeutics in a report on Wednesday, March 26th.

Atossa Therapeutics Price Performance

Shares of ATOS stock opened at $0.86 on Friday. Atossa Therapeutics, Inc. has a one year low of $0.55 and a one year high of $1.81. The stock has a fifty day moving average price of $0.70 and a 200 day moving average price of $0.96. The stock has a market cap of $110.49 million, a P/E ratio of -3.89 and a beta of 1.01.

Atossa Therapeutics (NASDAQ:ATOS) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. Equities research analysts anticipate that Atossa Therapeutics, Inc. will post -0.22 EPS for the current year.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.